4.6

CiteScore

2.2

Impact Factor
  • ISSN 1674-8301
  • CN 32-1810/R
Fanyu Peng, Yizhi Ge, Rongrong Wang, Dingdong Hu, Xiang Cao, Yujie Zhang, Dan Zong, Xia He. Identifying nasopharyngeal carcinoma patients with metachronous metastasis sensitive to local treatment: a real-world study[J]. The Journal of Biomedical Research, 2022, 36(4): 221-230. DOI: 10.7555/JBR.36.20220060
Citation: Fanyu Peng, Yizhi Ge, Rongrong Wang, Dingdong Hu, Xiang Cao, Yujie Zhang, Dan Zong, Xia He. Identifying nasopharyngeal carcinoma patients with metachronous metastasis sensitive to local treatment: a real-world study[J]. The Journal of Biomedical Research, 2022, 36(4): 221-230. DOI: 10.7555/JBR.36.20220060

Identifying nasopharyngeal carcinoma patients with metachronous metastasis sensitive to local treatment: a real-world study

More Information
  • Corresponding author:

    Xia He, Department of Radiation Oncology, Jiangsu Cancer Hospital, 42 Baiziting Road, Xuanwu District, Nanjing, Jiangsu 210009, China. Tel: +86-25-83284634, E-mail: hexiabm@163.com

  • Received Date: March 22, 2022
  • Revised Date: April 17, 2022
  • Accepted Date: April 27, 2022
  • Available Online: May 27, 2022
  • It is difficult for physicians to identify patients with metastatic nasopharyngeal carcinoma (NPC) who are sensitive to local treatment of metastases. Here, we aimed to establish a prognostic model for survival and individualize treatments for patients with metastatic NPC. Data were collated from 240 NPC patients diagnosed with metachronous metastasis between 2006 and 2020 who received palliative chemotherapy with or without local treatment. Multivariable Cox regression was implemented to construct a nomogram which had a concordance index of 0.764 when predicting 1-, 3-, and 5-year overall survival (OS). We then classified patients according to risk, creating low- and high-risk groups using the nomogram. Differences in OS between the two groups were significant (P<0.001). In the low-risk group, the OS for patients who received local treatment was longer than those without (P=0.009). This novel nomogram shows good performance in classifying patients according to risk and may also be a promising tool for determining who responds best to local treatment. Further validation using external center data is warranted.
  • CLC number: R739.6, Document code: A

    The authors reported no conflict of interests.

    These authors contributed equally to this work.

  • [1]
    Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394–424. doi: 10.3322/caac.21492
    [2]
    Mao Y, Tang L, Chen L, et al. Prognostic factors and failure patterns in non-metastatic nasopharyngeal carcinoma after intensity-modulated radiotherapy[J]. Chin J Cancer, 2016, 35(1): 103. doi: 10.1186/s40880-016-0167-2
    [3]
    Lee N, Xia P, Quivey JM, et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience[J]. Int J Radiat Oncol Biol Phys, 2002, 53(1): 12–22. doi: 10.1016/S0360-3016(02)02724-4
    [4]
    Lai S, Li W, Chen L, et al. How does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients?[J]. Int J Radiat Oncol Biol Phys, 2011, 80(3): 661–668. doi: 10.1016/j.ijrobp.2010.03.024
    [5]
    Wu L, Liu Y, Jiang N, et al. Ten-year survival outcomes for patients with nasopharyngeal carcinoma receiving intensity-modulated radiotherapy: an analysis of 614 patients from a single center[J]. Oral Oncol, 2017, 69: 26–32. doi: 10.1016/j.oraloncology.2017.03.015
    [6]
    Yeo W, Leung TWT, Leung SF, et al. Phase II study of the combination of carboplatin and 5-fluorouracil in metastatic nasopharyngeal carcinoma[J]. Cancer Chemother Pharmacol, 1996, 38(5): 466–470. doi: 10.1007/s002800050512
    [7]
    Hong S, Zhang Y, Yu G, et al. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin as first-line therapy for recurrent or metastatic nasopharyngeal carcinoma: final overall survival analysis of GEM20110714 phase III study[J]. J Clin Oncol, 2021, 39(29): 3273–3282. doi: 10.1200/JCO.21.00396
    [8]
    Au E, Ang PT. A phase Ⅱ trial of 5-fluorouracil and cisplatinum in recurrent or metastatic nasopharyngeal carcinoma[J]. Ann Oncol, 1994, 5(1): 87–89. doi: 10.1093/oxfordjournals.annonc.a058703
    [9]
    Weichselbaum R, Hellman S. Oligometastases revisited[J]. Nat Rev Clin Oncol, 2011, 8(6): 378–382. doi: 10.1038/nrclinonc.2011.44
    [10]
    You R, Liu Y, Huang P, et al. Efficacy and safety of locoregional radiotherapy with chemotherapy vs chemotherapy alone in de novo metastatic nasopharyngeal carcinoma: a multicenter phase 3 randomized clinical trial[J]. JAMA Oncol, 2020, 6(9): 1345–1352. doi: 10.1001/jamaoncol.2020.1808
    [11]
    Huang J, Li Q, Zheng Y, et al. Partial hepatectomy for liver metastases from nasopharyngeal carcinoma: a comparative study and review of the literature[J]. BMC Cancer, 2014, 14: 818. doi: 10.1186/1471-2407-14-818
    [12]
    Jin Y, Cai Y, Cao Y, et al. Radiofrequency ablation combined with systemic chemotherapy in nasopharyngeal carcinoma liver metastases improves response to treatment and survival outcomes[J]. J Surg Oncol, 2012, 106(3): 322–326. doi: 10.1002/jso.23034
    [13]
    Ma J, Wen Z, Lin P, et al. The results and prognosis of different treatment modalities for solitary metastatic lung tumor from nasopharyngeal carcinoma: a retrospective study of 105 cases[J]. Chin J Cancer, 2010, 29(9): 787–795. doi: 10.5732/cjc.010.10098
    [14]
    Lievens Y, Guckenberger M, Gomez D, et al. Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document[J]. Radiother Oncol, 2020, 148: 157–166. doi: 10.1016/j.radonc.2020.04.003
    [15]
    Guckenberger M, Lievens Y, Bouma AB, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation[J]. Lancet Oncol, 2020, 21(1): E18–E28. doi: 10.1016/S1470-2045(19)30718-1
    [16]
    Harrell FE Jr. Rms: Regression Modeling Strategies[EB/OL]. [2021-03-18]. https://github.com/harrelfe/rms.
    [17]
    Zhang J, Jin Z. nomogramFormula[EB/OL]. [2019-08-17]. https://github.com/yikeshu0611/nomogramFormula.
    [18]
    Du Z, Hao Y. nomogramEx: Extract Equations from a Nomogram[EB/OL]. [2017-08-29]. https://cran.r-project.org/web/packages/nomogramEx/index.html.
    [19]
    Zheng W, Zong J, Huang C, et al. Multimodality treatment may improve the survival rate of patients with metastatic nasopharyngeal carcinoma with good performance status[J]. PLoS One, 2016, 11(1): e0146771. doi: 10.1371/journal.pone.0146771
    [20]
    Tian Y, Zou W, Xiao W, et al. Oligometastases in AJCC stage IVc nasopharyngeal carcinoma: a subset with better overall survival[J]. Head Neck, 2016, 38(8): 1152–1157. doi: 10.1002/hed.24345
    [21]
    Zhao Z, Liu D, Wang Y, et al. Pulmonary metastasectomy in patients with lung metastases from nasopharyngeal carcinoma[J]. Ann Surg Oncol, 2021, 28(8): 4542–4550. doi: 10.1245/s10434-021-09597-5
    [22]
    Shen L, Dong J, Li S, et al. M1 stage subdivision and treatment outcome of patients with bone-only metastasis of nasopharyngeal carcinoma[J]. Oncologist, 2015, 20(3): 291–298. doi: 10.1634/theoncologist.2014-0206
    [23]
    Cao X, Han Y, He L, et al. Risk subset of the survival for nasopharyngeal carcinoma patients with bone metastases: who will benefit from combined treatment?[J]. Oral Oncol, 2011, 47(8): 747–752. doi: 10.1016/j.oraloncology.2011.05.010
    [24]
    Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial[J]. Lancet, 2019, 393(10185): 2051–2058. doi: 10.1016/S0140-6736(18)32487-5
    [25]
    Gomez DR, Tang C, Zhang J, et al. Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non–small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study[J]. J Clin Oncol, 2019, 37(18): 1558–1565. doi: 10.1200/JCO.19.00201
    [26]
    Iyengar P, Wardak Z, Gerber DE, et al. Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial[J]. JAMA Oncol, 2018, 4(1): e173501. doi: 10.1001/jamaoncol.2017.3501
    [27]
    Ruers T, van Coevorden F, Punt CJA, et al. Local treatment of unresectable colorectal liver metastases: results of a randomized phase Ⅱ trial[J]. J Natl Cancer Inst, 2017, 109(9): djx015. doi: 10.1093/jnci/djx015
    [28]
    Li W, Lv S, Liu G, et al. Development of a prognostic model to identify the suitable definitive radiation therapy candidates in de novo metastatic nasopharyngeal carcinoma: a real-world study[J]. Int J Radiat Oncol Biol Phys, 2021, 109(1): 120–130. doi: 10.1016/j.ijrobp.2020.08.045
    [29]
    Chee J, Liu X, Eu D, et al. Defining a cohort of oligometastatic nasopharyngeal carcinoma patients with improved clinical outcomes[J]. Head Neck, 2020, 42(5): 945–954. doi: 10.1002/hed.26061
  • Related Articles

    [1]Jiawei Li, Lili Feng, Yingmei Lu. Glioblastoma multiforme: Diagnosis, treatment, and invasion[J]. The Journal of Biomedical Research, 2023, 37(1): 47-58. DOI: 10.7555/JBR.36.20220156
    [2]Trupti N. Patel, Pavan Kumar Dhanyamraju. Role of aberrant Sonic hedgehog signaling pathway in cancers and developmental anomalies[J]. The Journal of Biomedical Research, 2022, 36(1): 1-9. DOI: 10.7555/JBR.35.20210139
    [3]Mehta Neha, Qiao Renli. Medical management of COVID-19 clinic[J]. The Journal of Biomedical Research, 2020, 34(6): 416-421. DOI: 10.7555/JBR.34.20200118
    [4]Vijayakumar Subramaniyan, Ramesh Venkatachalam, Prabhu Srinivasan, Manogar Palani. In silico prediction of monovalent and chimeric tetravalent vaccines for prevention and treatment of dengue fever[J]. The Journal of Biomedical Research, 2018, 32(3): 222-236. DOI: 10.7555/JBR.31.20160109
    [5]Mohammad Darvishi, Narges Vasei. Herpes zoster in breast cancer: a case report[J]. The Journal of Biomedical Research, 2017, 31(4): 370-372. DOI: 10.7555/JBR.31.20170009
    [6]Long Xie, Heming Wu, Siyu Liu, Hongwei Li. Spindle cell carcinoma of the mandible: a case report[J]. The Journal of Biomedical Research, 2017, 31(3): 273-276. DOI: 10.7555/JBR.30.20140061
    [7]Monica M. Mahathre, Padmashree C. G. Rida, Ritu Aneja. The more the messier: centrosome amplification as a novel biomarker for personalized treatment of colorectal cancers[J]. The Journal of Biomedical Research, 2016, 30(6): 441-451. DOI: 10.7555/JBR.30.20150109
    [8]Roderick Tung, Kalyanam Shivkumar. Neuraxial modulation for treatment of VT storm[J]. The Journal of Biomedical Research, 2015, 29(1): 56-60. DOI: 10.7555/JBR.29.20140161
    [9]Xiaojun Tang, Yan Zhou, Wenjie Li, Qi Tang, Renjie Chen, Jin Zhu, Zhenqing Feng. T cells expressing a LMP1-specific chimeric antigen receptor mediate antitumor effects against LMP1-positive nasopharyngeal carcinoma cells in vitro and in vivo[J]. The Journal of Biomedical Research, 2014, 28(6): 468-475. DOI: 10.7555/JBR.28.20140066
    [10]Shengfa Ni, Lingxiang Liu, Yongqian Shu. Sequential transcatheter arterial chemoembolization, three-dimensional conformal radiotherapy, and high-intensity focused ultrasound treatment for unresectable hepatocellular carcinoma patients[J]. The Journal of Biomedical Research, 2012, 26(4): 260-267. DOI: 10.7555/JBR.26.20120016
  • Other Related Supplements

Catalog

    Figures(5)  /  Tables(4)

    Article Metrics

    Article views (1514) PDF downloads (243) Cited by()
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return